ExitWednesday, June 10, 2026
GSK to acquire Deerfield-backed Nuvalent
GSK agreed to acquire Nuvalent, a precision oncology company backed by Deerfield Management, for $10.6 billion.
The deal gives Deerfield an exit and adds Nuvalent's targeted cancer therapy pipeline to GSK.
Deal facts
- Target
- Nuvalent
- Buyer
- GSK
- Seller
- Deerfield Management
- Deal type
- Exit
- Value
- $10.6 billion
- Status
- Announced, not yet closed
- Announced
- Wednesday, June 10, 2026
Sources
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.